Hansoh Pharmaceutical Group Company Limited (03692.HK)

Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 9,313 full-time employees. The company went IPO on 2019-06-14. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The firm mainly conducts its business in the domestic market.